precision medicine

Three tech-driven companies—Tempus AI, Recursion Pharmaceuticals, and Axsome Therapeutics—are positioned to reshape healthcare through AI, precision medicine, and faster drug discovery by 2030.

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.

Roche to acquire digital pathology company PathAI for $750M upfront plus $300M in milestones, strengthening AI-driven diagnostic capabilities and precision medicine strategy.

Global DNA microarray market projected to grow from $2.5B in 2025 to $4.7B by 2034 at 7% CAGR, driven by genomic research and personalized medicine demand.

Global targeted DNA-RNA sequencing market to surge from $8.6B in 2025 to $46.9B by 2035, driven by precision medicine adoption and government genomic initiatives.

Telix Pharmaceuticals' glioma imaging candidate TLX101-Px gains European regulatory validation, entering 210-day review phase with potential market approval expected.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Global biosimulation market projected to expand from $4.7B in 2025 to $20B by 2034 at 17% CAGR, driven by regulatory support and virtual trial adoption.

AI clinical trial feasibility market expands from $0.83B (2025) to $2.76B by 2030 at 27.3% CAGR, driven by precision medicine and decentralized trials.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

IOB scientists unveil MitoCatch, engineered technology delivering healthy mitochondria to damaged cells. Early data shows improved cell survival in disease models.

Tempus AI shares jumped 7.3% to $49.34 after 31 cancer research abstracts were accepted for AACR conference, though analyst coverage turns cautious.

Drug development services market projected to reach $50.26B by 2030 from $28.09B in 2025, driven by AI adoption, personalized medicine, and emerging market expansion.

Global NGS market projected to reach $29.5B by 2030 from $14.9B in 2025, with Asia-Pacific experiencing fastest growth driven by precision medicine adoption.

Trogenix publishes Nature data showing 83% complete tumor elimination in aggressive brain cancer model. Phase I/II trial dosing planned for Q2 2026.

Profusa shares crashed 40% Tuesday after announcing $30M all-equity deal to acquire BioInsights' multi-omics diagnostics platform, expanding into molecular cancer detection.

Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.

Praxis reports 77% placebo-adjusted seizure reduction in SCN2A epilepsy treatment with no serious safety events, advancing precision neurotherapy.

Kura Oncology granted 153,750 stock options at $8.34/share to six new employees under Nasdaq Rule 5635(c)(4), valued at approximately $1.28 million, with standard four-year vesting.